TPIV 200

Drug Profile

TPIV 200

Alternative Names: Folate receptor alpha vaccine; Folate receptor alpha-loaded dendritic cell vaccine; FR alpha peptide vaccine; FRa peptide vaccine; FRalphaDC; HuFR-1; Multi-epitope folate receptor alpha peptide vaccine; TPIV200

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mayo Clinic
  • Developer Mayo Clinic; TapImmune
  • Class Cancer vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Ovarian cancer
  • No development reported Fallopian tube cancer; Peritoneal cancer

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Ovarian-cancer(Monotherapy) in USA (Intradermal)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Second-line therapy or greater) in USA (Intradermal)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Peritoneal-cancer(Combination therapy, Second-line therapy or greater) in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top